The Patent Finder

Protein Design Labs, Inc.

Also on record
Records under this name other than patents Protein Design Labs, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Protein Design Labs, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,709,610Therapeutic Use of ANTI-CS1 Antibodies
Formerly held
In force
 · Low confidence
In forceLow confidence
US 7,399,469ANTI-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer
Formerly held
Term ended
Term ended Mar 29, 2026 · High confidence
Term endedTerm ended Mar 29, 2026High confidence
US 10,442,859Therapeutic Use of ANTI-CS1 Antibodies
Formerly held
Term ended
Term ended Aug 19, 2025 · Medium confidence
Term endedTerm ended Aug 19, 2025Medium confidence
US 7,276,372Antibodies Against GPR64 and Uses Thereof
Formerly held
Term ended
Term ended Jun 22, 2025 · High confidence
Term endedTerm ended Jun 22, 2025High confidence
US 7,276,589Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Formerly held
Term ended
Term ended Jan 11, 2025 · High confidence
Term endedTerm ended Jan 11, 2025High confidence
US 7,217,798Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Formerly held
Term ended
Ended no later than Oct 15, 2024 · Medium confidence
Term endedEnded no later than Oct 15, 2024Medium confidence
US 7,285,268Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Formerly held
Term ended
Term ended Sep 19, 2024 · High confidence
Term endedTerm ended Sep 19, 2024High confidence
US 7,288,248Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Formerly held
Term ended
Term ended Sep 1, 2024 · High confidence
Term endedTerm ended Sep 1, 2024High confidence
US 7,189,507Methods of Diagnosis of Ovarian Cancer, Compositions and Methods of Screening for Modulators of Ovarian Cancer
Formerly held
Term ended
Term ended Jul 12, 2024 · High confidence
Term endedTerm ended Jul 12, 2024High confidence
US 7,122,185ANTI-CCR5 Antibody
Formerly held
Term ended
Term ended Jun 1, 2024 · High confidence
Term endedTerm ended Jun 1, 2024High confidence
10 of 68 patents shown.
Pro members see all 68.
Pro members: see all 68 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited